Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

INVO Fertility (IVF) Other Non Operating Income (2017 - 2025)

Historic Other Non Operating Income for INVO Fertility (IVF) over the last 15 years, with Q3 2025 value amounting to -$876165.0.

  • INVO Fertility's Other Non Operating Income changed N/A to -$876165.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 million, marking a year-over-year decrease of 67122.62%. This contributed to the annual value of -$40491.0 for FY2024, which is 7520.12% up from last year.
  • INVO Fertility's Other Non Operating Income amounted to -$876165.0 in Q3 2025.
  • INVO Fertility's 5-year Other Non Operating Income high stood at $161339.0 for Q4 2021, and its period low was -$876165.0 during Q3 2025.
  • Over the past 5 years, INVO Fertility's median Other Non Operating Income value was -$888.0 (recorded in 2022), while the average stood at -$107769.4.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first surged by 33091.53% in 2021, then plummeted by 3000388.17% in 2023.
  • Quarter analysis of 5 years shows INVO Fertility's Other Non Operating Income stood at $161339.0 in 2021, then plummeted by 100.34% to -$541.0 in 2022, then tumbled by 30003.88% to -$162862.0 in 2023, then surged by 75.14% to -$40491.0 in 2024, then plummeted by 2063.85% to -$876165.0 in 2025.
  • Its last three reported values are -$876165.0 in Q3 2025, -$692270.0 for Q2 2025, and -$40491.0 during Q2 2024.